Welcome to our dedicated page for Kintara Therapeutics news (Ticker: KTRA), a resource for investors and traders seeking the latest updates and insights on Kintara Therapeutics stock.
Kintara Therapeutics, Inc. (Nasdaq: KTRA) generated frequent news as a biopharmaceutical company focused on developing new solid tumor cancer therapies and as the vehicle for a significant reverse merger with TuHURA Biosciences, Inc. Company press releases describe Kintara as located in San Diego, California and dedicated to novel cancer therapies for patients with unmet medical needs, with a lead program centered on REM-001 Therapy for cutaneous metastatic breast cancer (CMBC).
The KTRA news flow prominently features updates on REM-001 Therapy, including details of an open-label CMBC study, prior Phase 2/3 clinical experience, and the role of a Small Business Innovation Research grant from the National Institutes of Health in supporting study costs. These items provide context on the company’s proprietary late-stage photodynamic therapy platform, which combines a laser light source, a light delivery device, and the REM-001 drug product.
Another major theme in Kintara’s news coverage is its merger with TuHURA Biosciences, Inc. Articles outline the definitive merger agreement, stockholder meetings, voting instructions, and the strategic rationale for combining Kintara’s oncology assets with TuHURA’s Phase 3 registration-stage immuno-oncology programs. Releases discuss the expected ownership structure of the combined company, the planned corporate name change to TuHURA Biosciences, Inc., and the transition of trading to the Nasdaq Capital Market under the symbol HURA.
News items also detail corporate actions tied to the merger, including the approval and implementation of a 1-for-35 reverse stock split and the establishment of Contingent Value Rights (CVRs) to provide potential additional share consideration to Kintara stockholders upon achievement of specified REM-001 study milestones. Additional coverage includes reminders to stockholders to vote on key proposals, adjournments and reconvening of special meetings, and fiscal year financial results accompanied by corporate updates.
For readers following KTRA historically, this news archive offers insight into Kintara’s oncology development efforts, its financial and strategic decisions, and the sequence of events that led to the transformation of the Kintara listing into TuHURA Biosciences, Inc. under the HURA ticker. Regular review of these releases helps clarify how the company’s clinical programs and corporate structure evolved over time.
Kintara Therapeutics, Inc. (KTRA) announced the closure of a private placement, selling 2,185 shares of Series C Convertible Preferred Stock at $1,000 per share, raising approximately $2.2 million. This follows an earlier $19.6 million from a previous closing. The proceeds will fund a registration study for VAL-083 and a 15-patient study for REM-001, alongside working capital. Both therapies target significant medical needs, with VAL-083 in GBM and REM-001 in CMBC. The Preferred Stock is convertible at $1.214 per share and accrues dividends.
Kintara Therapeutics (KTRA) announced a private placement offering of up to 2,435 shares of Series C Convertible Preferred Stock at $1,000 per share, aiming for gross proceeds of approximately $2.4 million. This follows a previous raising of $19.6 million. The funds will support clinical studies for VAL-083 in glioblastoma and REM-001 for metastatic breast cancer. The offering is expected to close by August 24, 2020, pending customary conditions. Notably, the Preferred Stock is convertible into common stock at $1.214 per share, with accrued dividends as previously disclosed.
Kintara Therapeutics (KTRA) announced it has regained compliance with NASDAQ's minimum bid price requirement, as confirmed in a letter received on August 19, 2020. The company's shares closed above $1.00 for ten consecutive business days, satisfying Listing Rule 5550(a)(2). Kintara is focused on developing innovative cancer therapies, including VAL-083 for GBM and REM-001 for CMBC. Both programs are in advanced clinical stages, with VAL-083 showing promise in various cancers and REM-001 achieving an 80% complete response in prior studies.